National Certified Addiction Counselor, Level I (NCAC I) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Prepare for the National Certified Addiction Counselor, Level I (NCAC I) Exam with comprehensive flashcards and multiple choice questions. Each question comes with detailed explanations and hints. Get ready for your NCAC I certification!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.


Which of the following is a result of buprenorphine's partial agonist activity?

  1. Complete euphoria

  2. Limited withdrawal symptoms

  3. Complete sedation

  4. No impact on opioid receptors

The correct answer is: Limited withdrawal symptoms

Buprenorphine’s partial agonist activity leads to a unique effect on opioid receptors, which is key to understanding its role in addiction treatment. As a partial agonist, buprenorphine activates the opioid receptors but to a lesser extent than full agonists like morphine or heroin. This characteristic can effectively reduce withdrawal symptoms for individuals who are dependent on opioids, as it allows for sufficient receptor activation to alleviate cravings and discomfort associated with withdrawal without producing the intense euphoria associated with full agonists. This makes buprenorphine particularly useful in medication-assisted treatment for opioid use disorder, as it helps patients stabilize without the risks of overdose and the high potential for misuse seen with full agonists. The transition from dependency is more manageable, allowing for a smoother recovery process. While other choices suggest effects like complete euphoria, complete sedation, or no impact on opioid receptors, they do not accurately depict how buprenorphine functions. The goal of using buprenorphine in treatment is to strike a balance between providing enough relief from withdrawal and cravings while minimizing potential abuse and overdose risks. This demonstrates the importance of its partial agonist nature in facilitating safer and more effective treatment outcomes.